<DOC>
	<DOCNO>NCT01750567</DOCNO>
	<brief_summary>Metformin antidiabetic drug inexpensive generally well tolerated medication . More recently metformin show act carcinoma two mechanism : 1 ) indirect , insulin‐dependent mechanism sensitize tissue insulin , inhibit hepatic gluconeogenesis , stimulates uptake glucose muscle , thereby reduce fast blood glucose circulating level insulin , lower pro survival activity insulin/INSR axis , 2 ) direct , insulin‐independent mechanism activate AMP‐activated protein kinase ( AMPK ) pathway lead inhibition mTOR pathway . Given investigator preliminary publish data insulin mTOR inhibition [ 1 ] metformin attractive candidate pilot clinical trial CLL patient .</brief_summary>
	<brief_title>A Pilot Study Metformin Therapy Patients With Relapsed Chronic Lymphocytic Leukemia ( CLL ) Untreated CLL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Patients confirm diagnosis chronic lymphocytic leukemia define follow : ALC &gt; 5000 Positive either CD19 CD 20 together CD23 CD5 . Less 55 % atypical cell 2 . Patients relapse receive one course fludarabine , bendamustine , cytoxan , rituxan , chlorambucil , campath base therapy . 3 . Patients finding relapse one following : ALC &gt; 5000 2 consecutive occasion increase Any increase lymphadenopathy best response persist 3 month 4 . Patient confirm del11q mutation may include untreated . 5 . Age &gt; equal 18 year old &lt; 80 year age course therapy 6 . ECOG performance 0‐2 ( see Appendix A ) 7 . Life expectancy &gt; 12 month 8 . Patients must normal organ function define : AST ALT &lt; 2 time upper limit normal alkaline phosphatase &lt; 2 ULN serum bilirubin &lt; ULN ( exception Gilbert disease ) serum creatinine less equal 1.5 male , 1.4 female GFR &gt; 60 9 . Ability understand willingness sign write informed consent document 10 . Patient must able drink eat 75 % usual daily meal . 1 . Patients active CLL disease require urgent chemotherapy 2 . Patients may receive investigational agent . 3 . Patients less 30 day last treatment CLL . 4 . History allergic reaction attribute metformin biguanides . 5 . Known diabetes ( type 1 2 ) , fast glucose &gt; equal 7.0 mmol/L ( 126 mg/dL ) , HgbA1C &gt; 6.5 6 . Currently take metformin , sulfonylurea , thiazolidinediones insulin reason 7 . Current planned pregnancy lactation woman child bear age ( confirm negative pregnancy test prior start therapy ) . 8 . Uncontrolled intercurrent illness include , limited , ongoing active infection sepsis , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 9 . Conditions would increase risk lactic acidosis include : Known alcoholism ingestion 3 alcoholic beverage per day History congestive heart failure define NYHA class III IV 17 History metabolic acidosis Ongoing active infection concern sepsis SIRS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsed Chronic Lymphocytic Leukemia</keyword>
	<keyword>untreated CLL patient</keyword>
	<keyword>genomic deletion 11q</keyword>
</DOC>